New real world evidence validates pivotal clinical trial outcomes for Brilinta in MI patients

15 August 2016

Real world evidence recently published in the European Heart Journal demonstrates that AstraZeneca’s (LSE: AZN) Brilinta (ticagrelor) is associated with a lower risk of all-cause death, re-admission with myocardial infarction (MI) or stroke (composite endpoint), compared to clopidogrel, in the treatment of people with MI.

The PRACTICAL study prospectively measured outcomes from the Swedish registry of 45,073 patients with MI, SWEDEHEART. The study recorded outcomes from 11,954 acute coronary syndrome (ACS) patients discharged on ticagrelor and 33,119 on clopidogrel from 2010 to 2013. The results showed:

Compared with clopidogrel, ticagrelor was associated at two years with a lower risk of all-cause death, readmission with MI or stroke, as well as death alone; and
Consistent results at 12 months, with the primary efficacy endpoint occurring in 5.6 patients per 100 patient-years with ticagrelor versus 16.8 patients per 100 patient-years with clopidogrel.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK